Based on the earnings transcript for Amgen Inc., the company reported strong financial performance with a 14% increase in total revenues and a 26% increase in adjusted earnings per share (EPS) in the first quarter of 2006. The management highlighted the growth in key products such as Aranesp, Neulasta, and EPOGEN, as well as the successful acquisition of Abgenix. The company also provided an update on its pipeline, including the approval of panitumumab for third-line metastatic colorectal cancer and the progress of denosumab in various indications. However, the company faces challenges such as the potential impact of biosimilars in the EU and the need to navigate the reimbursement environment. The stock is likely to face short-term pressure due to the uncertainty surrounding the legal battle with Roche and the potential impact of biosimilars. The guidance for the full year 2006 was also lowered due to the acquisition of Abgenix. Overall, the stock is likely to experience a neutral to slightly negative impact in the short term.